top of page
Abstract Structure

Transaction and News

Chinese Tigermed Completes Acquisition of Japanese CRO Micron

August 4, 2025 at 8:40:00 AM

Tigermed (300347.SZ / 3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, today announces the completion of its acquisition of CRO company Micron,Inc.

Founded in 2005 and headquartered in Tokyo, Micron is a Japan-based Contract Research Organization (CRO) focusing in medical imaging and clinical trial services with over 160 employees. Micron brings nearly two decades of expertise in clinical research and the largest team of imaging experts in Asia, served more than 250 clients and contributed to the successful approval of over 40 drugs.

As the first imaging CRO in Japan, Micron has built a strong reputation for technology excellence and pioneering practices in imaging biomarkers, AI-powered imaging support, and long-standing client trust.

Following the acquisition, Micron will be integrated into Tigermed's global network as a key entity under Tigermed Japan. Leveraging mature service team and deep regional expertise from Micron, as well as its worldwide operational layout, Tigermed will enhance its coverage across Japan and Asia-Pacific in medical imaging capabilities.

- PR Newswire -

About Collabrium Partners

 

Collabrium Partners is a Chinese leading independent investment banking firm focused on providing financial advisories on mergers & acquisitions, strategic planning, restructuring, private placement, independent opinions to corporations, financial institutions, public service agencies, and others.

 

For more information, please visit www.collabrium.com

Image by Sahand Hoseini
logo_blue & gold.png

Company

Business

Legal

Location

Collabrium Partners & Co. Limited

9/F, Surson Commercial Building
140-142 Austin Road,
Tsim Sha Tsui, Kowloon,
Hong Kong

© 2019 Collabrium Partners & Co. Limited all rights reserved.

Mergers & Acquisitions
Strategic Advisory
Capital Restructuring
Private Placement
Special Committee
Independent Advice
Privacy Policy
Other Notices
Hong Kong
Beijing
Shanghai
Shenzhen
New York
London
Dubai
bottom of page